AlloHeme™
AI-Powered Relapse Prediction for Post-Cell Therapy AML & MDS Patients
AlloHeme™ is a minimally invasive, blood-based monitoring test designed to help predict relapse risk in patients following allogeneic hematopoietic cell transplantation (HCT).
By combining next‑generation sequencing with a proprietary AI-derived algorithm trained on longitudinal whole blood and cell subtype analyses, AlloHeme helps clinicians identify potential relapse risk earlier in the post‑allogeneic HCT course.
A New Era of Cell Therapy Monitoring
Relapse remains a primary clinical concern and a leading cause of mortality for AML and MDS patients following allogeneic HCT.
Although patients are followed closely with routine visits and blood work, the most informative assessments for relapse—such as bone marrow biopsy—are performed less often because they are invasive and logistically burdensome. This results in sub-optimal relapse monitoring.
AlloHeme is designed to provide a sensitive, minimally invasive, and universally applicable surveillance approach through a simple blood draw.
Universal, Minimally Invasive Insight
AlloHeme is built to fit seamlessly within routine post‑HCT practice:
Blood‑based (no bone marrow required)
Broadly applicable without the need for tumor-specific mutation targets
Enables early relapse prediction with high sensitivity
The Growing Population Who Needs It
The number of patients undergoing allogeneic HCT continues to rise, driven by:
A growing AML & MDS population
Increasing referrals with molecular risk stratification
Expanding donor options
Improved overall survival outcomes
The CareDx Transplant+ Precision Medicine Portfolio
The CareDx Transplant+ portfolio includes novel solutions for allogeneic HCT and CAR-T cell therapy, including persistence monitoring in hematologic malignancies, and beyond. AlloHeme is part of CareDx’s Transplant+ strategy, expanding the company’s precision medicine capabilities into cell therapy, hematology, and oncology. CareDx’s initial Transplant+ focus in cell therapy includes allogeneic HCT and CAR‑T care pathways at specialized centers where patients are followed longitudinally.
Partner With CareDx
CareDx partners with leading academic and biopharma groups to advance innovative monitoring strategies into transplant and cell therapy care.
Interested in exploring a collaboration?
Contact us about AlloHeme™ and other Transplant+ programs.
Watch the AlloHeme Investor Webcast
Get the full scientific and commercial overview directly from our leadership team.